In a patient with seronegative arthritis on sulfasalazine who presents with severe headache and abdominal pain, what are the differential diagnoses?

Differential Diagnoses for Severe Headache and Abdominal Pain in a Seronegative Arthritis Patient on Sulfasalazine

The most critical differential to consider is sulfasalazine-induced hypersensitivity reaction, specifically Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome or sulfasalazine-induced aseptic meningitis (SIAM), both of which can present with these symptoms and require immediate drug cessation.

Primary Sulfasalazine-Related Differentials

1. Sulfasalazine-Induced Aseptic Meningitis (SIAM)

• Classic presentation: Severe headache, fever, and systemic symptoms occurring within the first weeks to months of starting sulfasalazine 1, 2
• Key features to assess:
  • Fever and tachycardia
  • Meningeal signs (neck stiffness, photophobia)
  • Timing: typically occurs 2-8 weeks after drug initiation 3
  • CSF analysis shows mononuclear pleocytosis with elevated protein and normal glucose 2
  • All infectious workup (bacterial, viral PCR) returns negative 1, 2
• Associated findings: May present with mesenteric panniculitis on CT imaging 1

2. DRESS Syndrome (Drug Rash with Eosinophilia and Systemic Symptoms)

• Presentation: Fever, headache, abdominal pain with multi-organ involvement 4, 5
• Critical features to identify:
  • Skin rash (may be absent initially) 6
  • Eosinophilia and atypical lymphocytes 5
  • Hepatitis (elevated transaminases) 3, 5
  • Lymphadenopathy 5
  • Renal involvement possible 3
  • Respiratory symptoms (dyspnea, cough) 4
• Timing: Typically 2-8 weeks after starting sulfasalazine 3, 5
• Mortality: 10% mortality rate if not recognized and treated 3, 5

3. Sulfasalazine-Induced Hepatotoxicity

• Presentation: Abdominal pain (right upper quadrant), headache, fever 6, 7
• Laboratory findings:
  • Elevated liver enzymes (AST, ALT, GGT, alkaline phosphatase, bilirubin) 6
  • Can progress to hepatic necrosis or failure 6
  • May mimic autoimmune hepatitis due to positive baseline autoantibodies in rheumatologic patients 7

4. Sulfasalazine-Induced Blood Dyscrasias with Sepsis

• Presentation: Fever, headache, abdominal pain in context of infection 6
• Critical warning signs 6:
  • Sore throat
  • Pallor
  • Purpura
  • Fever
• Mechanism: Agranulocytosis or neutropenia leading to serious infections including sepsis and pneumonia 6, 8
• Timing: Can occur after 6 weeks despite initially normal counts 8

Non-Drug Related Differentials to Exclude

5. Infectious Causes

• Bacterial meningitis: Must be excluded urgently with CSF analysis
• Viral meningitis/encephalitis: HSV, enterovirus testing
• Intra-abdominal sepsis: Given history of recurrent UTIs 1, consider pyelonephritis, diverticulitis, cholecystitis
• Pneumonia with systemic symptoms

6. Autoimmune Disease Flare

• CNS vasculitis: Associated with underlying seronegative arthritis
• Lupus-associated complications: If patient has overlap syndrome features
• Inflammatory bowel disease: Given association with seronegative arthritis, consider IBD with complications

7. Other Serious Causes

• Subarachnoid hemorrhage: Sudden severe headache
• Acute pancreatitis: Abdominal pain radiating to back (sulfasalazine can cause this) 6
• Mesenteric ischemia: Severe abdominal pain in older patients

Diagnostic Approach Algorithm

Immediate actions:

1. Discontinue sulfasalazine immediately while awaiting workup 6
2. Complete blood count with differential (looking for eosinophilia, agranulocytosis, atypical lymphocytes)
3. Comprehensive metabolic panel (hepatic and renal function)
4. Blood cultures if febrile
5. Lumbar puncture with CSF analysis (cell count, protein, glucose, Gram stain, culture, viral PCR)
6. CT head (exclude hemorrhage/mass effect before LP)
7. CT chest/abdomen/pelvis (exclude infection source, assess for mesenteric panniculitis, hepatosplenomegaly, lymphadenopathy)

If infectious workup negative and sulfasalazine-induced reaction suspected:

• Initiate IV corticosteroids (produces dramatic improvement in SIAM and DRESS) 1, 5
• Monitor for clinical improvement within 24-48 hours of drug cessation and steroid initiation
• If agranulocytosis present: add G-CSF and broad-spectrum antibiotics for febrile neutropenia 8

Critical Pitfalls to Avoid

• Do not delay discontinuation of sulfasalazine while awaiting test results if hypersensitivity reaction suspected 6
• Do not mistake DRESS for viral infection - the similarity in presentation causes diagnostic delays 5
• Do not assume positive autoantibodies indicate autoimmune hepatitis in rheumatologic patients - these may be baseline findings, and drug toxicity must be excluded first 7
• Do not restart sulfasalazine after resolution - hypersensitivity reactions contraindicate future use 6
• Monitor complete blood counts even if initially normal - agranulocytosis can develop after weeks of therapy 8

The FDA label explicitly warns that deaths have been reported from hypersensitivity reactions, blood dyscrasias, and hepatotoxicity with sulfasalazine, and emphasizes that signs such as fever, headache, and abdominal symptoms warrant immediate investigation and drug discontinuation 6.